Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hypersensitivity Reaction
  Free Subscription

Articles published in
J Am Acad Dermatol
    October 2025
  1. HSIEH TS, Lee HY, Abe R, Takei S, et al
    Development and validation of prognostic models using novel inflammatory markers for drug reactions with eosinophilia and systemic symptoms: An international multicenter cohort study.
    J Am Acad Dermatol. 2025;93:1027-1034.
    >> Share

    September 2025
  2. NOEL WC 2ND, Shah A, Bercovitch L, Garza-Mayers AC, et al
    Health Insurance Coverage of Topical Medications in Vitiligo and Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Sep 19:S0190-9622(25)02864.
    >> Share

  3. HAGINO T, Uchiyama A, Kosaka K, Araki T, et al
    A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naive versus -experienced patients.
    J Am Acad Dermatol. 2025 Sep 15:S0190-9622(25)02822.
    >> Share

  4. LU J, Wang Y, Zhou C, Deng L, et al
    Increased Cancer Risk and Mortality in Individuals with Atopic Dermatitis: Evidence from the NHANES.
    J Am Acad Dermatol. 2025 Sep 1:S0190-9622(25)02726.
    >> Share

    August 2025
  5. CHANG JW, Wang F
    Response to Wang et al., "Comments on 'Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis'".
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02699.
    >> Share

  6. BISSONNETTE R, Goleva E, Berdyshev E, Leung DYM, et al
    In response to: "Response to Bissonnette et al. Dupilumab treatment restores lesional and non-lesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy.
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02705.
    >> Share

  7. CLABBERS J, Boesjes C, van Geel M, de Bruin-Weller M, et al
    Response to Bissonnette et al. 'Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, p
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02703.
    >> Share

  8. WANG Y, Liu Z
    Comments on "Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis".
    J Am Acad Dermatol. 2025 Aug 29:S0190-9622(25)02698.
    >> Share

  9. SHIVE M, Hawryluk E, Drucker AM, Frazer-Green L, et al
    Response to Chu et al's "Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based r
    J Am Acad Dermatol. 2025 Aug 27:S0190-9622(25)02552.
    >> Share

  10. BRUSTAD N, Wang T, Chen L, Kaiser H, et al
    Effect of prenatal high-dose vitamin D on childhood atopic dermatitis is modified by maternal cotinine metabolome: A secondary analysis of a randomized clinical trial.
    J Am Acad Dermatol. 2025 Aug 25:S0190-9622(25)02670.
    >> Share

  11. CHEN TL, Ma SH, Ou WF, Chen CC, et al
    Decreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study.
    J Am Acad Dermatol. 2025 Aug 18:S0190-9622(25)02646.
    >> Share

  12. BRAUN N, Lin C, Baker N, Peacker BL, et al
    Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes.
    J Am Acad Dermatol. 2025 Aug 18:S0190-9622(25)02645.
    >> Share

  13. BENANDI K, Spires A, Hansen A, Linfante A, et al
    Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network.
    J Am Acad Dermatol. 2025 Aug 12:S0190-9622(25)02388.
    >> Share

  14. CHANG JW, Wang F
    Response to Goleva et al., "Response to Chang et al's 'Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis'".
    J Am Acad Dermatol. 2025 Aug 7:S0190-9622(25)02558.
    >> Share

  15. GOLEVA E, Berdyshev E, Kreimer S, Leung DYM, et al
    Response to Chang et al's "Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis".
    J Am Acad Dermatol. 2025 Aug 6:S0190-9622(25)02557.
    >> Share

  16. GROLEAU AS, Mereniuk A, Makhzoum JP
    Current therapeutic options for adult patients with urticarial vasculitis: A scoping review.
    J Am Acad Dermatol. 2025;93:423-428.
    >> Share

    July 2025
  17. HAGINO T, Saeki H, Fujimoto E, Kanda N, et al
    Effectiveness of Tralokinumab for Upadacitinib-Refractory Atopic Dermatitis: 48-week Retrospective Study.
    J Am Acad Dermatol. 2025 Jul 19:S0190-9622(25)02528.
    >> Share

  18. XIONG G, Gupta S, Rao V, Abu-Hilal M, et al
    Topical Ruxolitinib is More Effective at Itch Reduction than Topical Roflumilast in Atopic Dermatitis: A Comparative Meta-Analysis.
    J Am Acad Dermatol. 2025 Jul 3:S0190-9622(25)02402.
    >> Share

    June 2025
  19. WEBER B, Karels S, Shaik J, Neeley A, et al
    Formaldehyde Allergic Contact Dermatitis: Evaluation of Paper-Based Menstrual Products as a Potential Route of Exposure.
    J Am Acad Dermatol. 2025 Jun 25:S0190-9622(25)02387.
    >> Share

  20. SUN C, Zhang X, Su Z, Yao WH, et al
    Global, regional and national burdens of atopic dermatitis from 1990 to 2021: a trend analysis from the Global Burden of Disease Study 2021.
    J Am Acad Dermatol. 2025 Jun 19:S0190-9622(25)02369.
    >> Share

  21. DAVIS DMR, Frazer-Green L, Alikhan A, Bercovitch L, et al
    Focused update: Guidelines of care for the management of atopic dermatitis in adults.
    J Am Acad Dermatol. 2025 Jun 17:S0190-9622(25)02125.
    >> Share

  22. MANN C, Wollenberg A, Stander S, Staubach P, et al
    Risk of developing sleep disorders and psychologic comorbidity in children with inflammatory skin diseases-A population-based study.
    J Am Acad Dermatol. 2025;92:1261-1268.
    >> Share

    May 2025
  23. PALLER AS, Siegfried EC, Cork MJ, Kabashima K, et al
    Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of three clinical trials.
    J Am Acad Dermatol. 2025 May 27:S0190-9622(25)02204.
    >> Share

  24. RIGALI S, Liszewski W
    Allergens in hair relaxer products: a potential source of allergic contact dermatitis in patients with textured hair.
    J Am Acad Dermatol. 2025 May 22:S0190-9622(25)02191.
    >> Share

  25. BISSONNETTE R, Gold LS, Kircik L, Simpson EL, et al
    Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis.
    J Am Acad Dermatol. 2025 May 16:S0190-9622(25)02130.
    >> Share

  26. EICHENFIELD LF, Stein Gold LF, Simpson EL, Zaenglein AL, et al
    Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study.
    J Am Acad Dermatol. 2025 May 14:S0190-9622(25)02124.
    >> Share

  27. KARELS S, Weber B, Ophaug S, Lee K, et al
    Evaluation of Nickel Content in Commercial Razors: Implications for Dermatologic Management of Nickel Allergy.
    J Am Acad Dermatol. 2025 May 10:S0190-9622(25)02107.
    >> Share

  28. ISLAM RK, Magharehabed Y, Islam KN, Joseph JM, et al
    Increased risk of type 2 diabetes in patients with atopic dermatitis: An age-stratified analysis using TriNetX.
    J Am Acad Dermatol. 2025 May 7:S0190-9622(25)00709.
    >> Share

  29. KALTCHENKO M, Radtke S, Kim E, Wan J, et al
    Response to Lai and Wei's "Comment on Kaltchenko et al.'s 'Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis.".
    J Am Acad Dermatol. 2025 May 5:S0190-9622(25)00692.
    >> Share

  30. LAI IC, Wei JC
    Comment on Kaltchenko et al.'s "Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis.".
    J Am Acad Dermatol. 2025 May 4:S0190-9622(25)00691.
    >> Share

    April 2025
  31. JOSHI A, Gawey L, Rahman M, Ghanshani R, et al
    Post-Marketing Safety Analysis of Upadacitinib in Atopic Dermatitis: An FDA Adverse Reporting System (FAERS) Review of Boxed Warning Related Adverse Events.
    J Am Acad Dermatol. 2025 Apr 25:S0190-9622(25)00681.
    >> Share

  32. CHANG JW, Huang X, Jiang W, Lun L, et al
    Abrocitinib versus dupilumab: impact on skin barrier function and proteomics in atopic dermatitis.
    J Am Acad Dermatol. 2025 Apr 15:S0190-9622(25)00621.
    >> Share

  33. JIN Y
    Considerations on the Potential Link Between Dupilumab and Cutaneous T-cell Lymphoma in Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Apr 4:S0190-9622(25)00563.
    >> Share

  34. NICHOLAS A, Fleischer AB Jr
    Race and appointment availability influence continuity of care for chronic inflammatory skin disease: A cross-sectional study of United States practice data.
    J Am Acad Dermatol. 2025;92:753-760.
    >> Share

  35. LI R, Zhang J, Wang L, Zhang LY, et al
    Comments on "Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: a real-world cohort analysis".
    J Am Acad Dermatol. 2025 Apr 1:S0190-9622(25)00554.
    >> Share

  36. KALTCHENKO M, Kim E, Radtke S, Wan J, et al
    Response to Li et al.'s "Comments on 'Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: A real-world cohort analysis".
    J Am Acad Dermatol. 2025 Apr 1:S0190-9622(25)00555.
    >> Share

    March 2025
  37. KANTOR J
    This Month in JAAD International: June 2025: Atopic dermatitis, puberty, and the benefits of nationwide cohort studies.
    J Am Acad Dermatol. 2025 Mar 29:S0190-9622(25)00551.
    >> Share

  38. HERMAN KE, Beck LA, Jarvinen KM
    Updates to the role of diet in atopic dermatitis.
    J Am Acad Dermatol. 2025 Mar 29:S0190-9622(25)00550.
    >> Share

  39. YOUN CG, Pour Mohammad A, Marqueling AL, Siegel DH, et al
    Association Between Supplemental Nutrition Assistance Program (SNAP) and Cost-Related Medical Care Delays in Pediatric Atopic Dermatitis: A Cross-Sectional Analysis of the National Health Interview Survey, 1999-2018.
    J Am Acad Dermatol. 2025 Mar 15:S0190-9622(25)00446.
    >> Share

  40. GUPTA S, Xiong G, Shenouda C, Keow S, et al
    Ruxolitinib versus Roflumilast: A Meta-analysis of the Comparative Efficacy of Two Topical Therapies for Atopic Dermatitis.
    J Am Acad Dermatol. 2025 Mar 14:S0190-9622(25)00438.
    >> Share

    February 2025
  41. DAHABREH D, Lo JC, Chandra M, Chiou AS, et al
    Atopic Dermatitis Prevalence among Asian American and Pacific Islander Children: A Retrospective Study in a Northern California Healthcare System.
    J Am Acad Dermatol. 2025 Feb 9:S0190-9622(25)00256.
    >> Share

  42. LIAO V, Lavin L, Pulitzer MP, Stuver R, et al
    Diagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center.
    J Am Acad Dermatol. 2025 Feb 1:S0190-9622(25)00188.
    >> Share

  43. RAU A, Leahr G, Del Pozo D, Hoffstad O, et al
    Atopic Dermatitis: Association of maternal and child history of celiac disease and the child's development of atopic dermatitis.
    J Am Acad Dermatol. 2025 Feb 1:S0190-9622(25)00178.
    >> Share

    January 2025
  44. LI Z, Xiao Y, Chen X, Gu X, et al
    Temporal Trends in the Prevalence and Burden of Atopic Dermatitis Worldwide from 1990 to 2021.
    J Am Acad Dermatol. 2025 Jan 31:S0190-9622(25)00163.
    >> Share

  45. SANDLER M, Kim EJ, Chen LC, Yu J, et al
    Discrepancies in Patch Testing Timing and Outcomes: A Retrospective Analysis of the Pediatric Allergic Contact Dermatitis Registry.
    J Am Acad Dermatol. 2025 Jan 31:S0190-9622(25)00165.
    >> Share

  46. HAGINO T, Saeki H, Fujimoto E, Kanda N, et al
    A 96-week real-world outcome of upadacitinib treatment for atopic dermatitis: systemic therapy-naive versus -experienced patients.
    J Am Acad Dermatol. 2025 Jan 27:S0190-9622(25)00132.
    >> Share

  47. SOOD S, Wiseman M, Bagit A, Maliyar K, et al
    Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study.
    J Am Acad Dermatol. 2025 Jan 24:S0190-9622(25)00131.
    >> Share

  48. BISSONNETTE R, Goleva E, Berdyshev E, Garcia S, et al
    Dupilumab treatment restores lesional and non-lesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD
    J Am Acad Dermatol. 2025 Jan 22:S0190-9622(25)00113.
    >> Share

  49. RODRIGUEZ R, Szeto MD, Hydol-Smith J, Burnette C, et al
    Higher Odds of Dupilumab Prescriptions for Black Patients with Atopic Dermatitis: Results of a Retrospective Study Using DataDerm, The Database of The American Academy of Dermatology.
    J Am Acad Dermatol. 2025 Jan 21:S0190-9622(25)00105.
    >> Share

  50. KALTCHENKO M, Radtke S, Kim E, Wan J, et al
    Dupilumab and neuropsychiatric outcomes in pediatric atopic dermatitis: a real-world cohort analysis.
    J Am Acad Dermatol. 2025 Jan 18:S0190-9622(25)00104.
    >> Share

  51. PHAN S, Hajek A, Rangel SM, Ren Z, et al
    Stigma Underlies the Mental Health Burden of Pediatric Atopic Dermatitis: A Cohort Study.
    J Am Acad Dermatol. 2025 Jan 3:S0190-9622(25)00004.
    >> Share

    December 2024
  52. GUTTMAN-YASSKY E, Rosmarin D, de Bruin-Weller M, Weidinger S, et al
    The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in two randomized controlled clinical trials.
    J Am Acad Dermatol. 2024 Dec 27:S0190-9622(24)03414.
    >> Share

  53. WU PA, Wu J, Liu R, Sullivan S, et al
    Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the diagnosis of allergic contact dermatitis: A series of 170 clinically- and patch test-confirmed cases.
    J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03379.
    >> Share

    November 2024
  54. BRODELL RT
    JAAD Game Changers: "Diet in dermatology: Part I. Atopic dermatitis, acne, and nonmelanoma skin cancer".
    J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03276.
    >> Share

  55. CHOI UE, Deng J, Parthasarathy V, Liao V, et al
    Risk factors and temporal associations of progression of the atopic march in children with early-onset atopic dermatitis.
    J Am Acad Dermatol. 2024 Nov 28:S0190-9622(24)03273.
    >> Share

  56. MASISON J, Beltrami EJ, Gronbeck C, Feng H, et al
    Differential patient travel burden to pediatric atopic dermatitis clinical trial sites.
    J Am Acad Dermatol. 2024 Nov 8:S0190-9622(24)03109.
    >> Share

    October 2024
  57. SINGAL A, Lipner HI, Neubauer Z, Lipner SR, et al
    Higher Sodium Excretion Is Not Associated With Increased Odds of Developing Atopic Dermatitis in a Large Retrospective Cohort Study.
    J Am Acad Dermatol. 2024 Oct 21:S0190-9622(24)03032.
    >> Share

  58. PALLER AS, de Bruin-Weller M, Marcoux D, Baselga E, et al
    Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDISTAD.
    J Am Acad Dermatol. 2024 Oct 8:S0190-9622(24)02919.
    >> Share

  59. ELGHAZZAWY MB, Nassir S, Arora JS, Min MS, et al
    A retrospective cohort study investigating cutaneous vasculitis in the setting of COVID-19 notes higher rates of IgA vasculitis.
    J Am Acad Dermatol. 2024;91:757-759.
    >> Share

  60. OBIJIOFOR CE, Sikora M, Liu L, Stern MJ, et al
    Investigating corrected QT prolongation with hydroxychloroquine use among patients with cutaneous sarcoidosis: A multicenter retrospective study.
    J Am Acad Dermatol. 2024;91:740-742.
    >> Share

    September 2024
  61. NGUYEN TV, Marcus AF, Sinnott SJ, Coleman A, et al
    Commentary: Response to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study".
    J Am Acad Dermatol. 2024 Sep 30:S0190-9622(24)02901.
    >> Share

  62. PALLER AS, Silverberg JI, Simpson EL, Cork MJ, et al
    The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study.
    J Am Acad Dermatol. 2024 Sep 28:S0190-9622(24)02896.
    >> Share

  63. GUILLEMIN C, Bellon N, Jachiet M, Barbarot S, et al
    Dupilumab in atopic-dermatitis-like eczema associated with inborn errors of immunity: a nationwide study.
    J Am Acad Dermatol. 2024 Sep 27:S0190-9622(24)02885.
    >> Share

  64. NEUBAUER ZJK, Brunner PM, Geskin LJ, Guttman E, et al
    Decoupling the Association of Dupilumab with Cutaneous T-Cell Lymphoma Reply to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study.".
    J Am Acad Dermatol. 2024 Sep 7:S0190-9622(24)02812.
    >> Share

  65. MATEI I, Bettuzzi T, Peiffer B, Ingen-Housz-Oro S, et al
    Evolution of the spectrum of drugs associated with acute generalized exanthematous pustulosis over time: A pharmacovigilance study.
    J Am Acad Dermatol. 2024;91:555-557.
    >> Share

  66. INGEN-HOUSZ-ORO S, Guichard E, Milpied B, Bensaid B, et al
    Topical versus oral corticosteroids in moderate drug reaction with eosinophilia and systemic symptoms: A multicenter randomized clinical trial.
    J Am Acad Dermatol. 2024;91:544-547.
    >> Share

    August 2024
  67. MA EZ, Bao A, Ahmadi M, Zhang J, et al
    Dupilumab is associated with reduced risk of acute upper respiratory infections in atopic dermatitis patients compared to non-targeted immunosuppressants: a multi-center cohort study.
    J Am Acad Dermatol. 2024 Aug 30:S0190-9622(24)02756.
    >> Share

  68. HASAN I, Zinn Z
    Response to Flynn et al. "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Aug 27:S0190-9622(24)02727.
    >> Share

  69. CHO YT, Chu CY
    Comments on "dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T-cell lymphoma: a retrospective cohort study".
    J Am Acad Dermatol. 2024 Aug 24:S0190-9622(24)02739.
    >> Share

  70. FLYNN E, Leonard N, Svoboda R
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Aug 23:S0190-9622(24)02726.
    >> Share

  71. CHAIYABUTR C, Dawe R, Lesar A, Ibbotson SH, et al
    Continuum of Light Sensitivity in Atopic Dermatitis: A Retrospective Analysis of 139 Cases in Scotland.
    J Am Acad Dermatol. 2024 Aug 22:S0190-9622(24)02710.
    >> Share

  72. SEE TOW HX, Yeok-Loo Lim A, Ci-En Choi E
    Response to: Bocquel et al., "Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study".
    J Am Acad Dermatol. 2024 Aug 21:S0190-9622(24)02661.
    >> Share

  73. GEORGE SE, Yu J
    Tralokinumab as an Effective Alternative after Dupilumab Treatment Failure in Moderate-to-Severe Atopic Dermatitis: A Real-World Study.
    J Am Acad Dermatol. 2024 Aug 20:S0190-9622(24)02700.
    >> Share

  74. RIVA HR, Woodruff CM
    Allergens and consumer warnings in at-home acrylic manicure kits.
    J Am Acad Dermatol. 2024 Aug 13:S0190-9622(24)02655.
    >> Share

  75. KRIDIN K, Ludwig RJ
    Reply to: "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study".
    J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02574.
    >> Share

  76. CHEN TL, Ma SH
    Comments on the risk of cutaneous T cell lymphoma among patients with atopic dermatitis receiving dupilumab.
    J Am Acad Dermatol. 2024 Aug 6:S0190-9622(24)02573.
    >> Share

  77. HEYMANN WR
    Dupilumab's duplicity.
    J Am Acad Dermatol. 2024;91:249-250.
    >> Share

  78. SAMARAKOON U, Wolfson AR, Zhou L, Bassir F, et al
    Understanding the patient experience of drug reaction with eosinophilia and systemic symptoms: A qualitative study.
    J Am Acad Dermatol. 2024;91:370-373.
    >> Share

  79. GEORGE SE, Yu J
    Patch testing outcomes in children at the Massachusetts General Hospital.
    J Am Acad Dermatol. 2024;91:354-356.
    >> Share

    July 2024
  80. ZIEBART RL, Haberecht H, Davis MD, Wetter DA, et al
    Vancomycin-Associated Drug induced Hypersensitivity Syndrome: A Retrospective Cohort Study.
    J Am Acad Dermatol. 2024 Jul 29:S0190-9622(24)02556.
    >> Share

  81. PEZZOLO E, Narcisi A, Gargiulo L, Di Lernia V, et al
    Successful response to upadacitinib in patients affected by prurigo nodularis and by atopic dermatitis with a predominant prurigo nodularis pattern: a multicenter case series study.
    J Am Acad Dermatol. 2024 Jul 22:S0190-9622(24)02538.
    >> Share

  82. ZHAO Y, Zhang L, Zhang J
    Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
    J Am Acad Dermatol. 2024 Jul 20:S0190-9622(24)02498.
    >> Share

  83. WU KJ, Wei KC
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 19:S0190-9622(24)02496.
    >> Share

  84. MEROLA JF, Chiou AS, During E, Foley P, et al
    Improved sleep parallels improvements in atopic dermatitis signs, symptoms, and quality of life in adult patients treated with dupilumab: 24-week results from the DUPISTAD study.
    J Am Acad Dermatol. 2024 Jul 13:S0190-9622(24)02483.
    >> Share

  85. SHIH PC, Wei JCC
    Response to Hasan et al.'s "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 11:S0190-9622(24)01041.
    >> Share

  86. HASAN I, Zinn Z
    Response to Shih et al. "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.".
    J Am Acad Dermatol. 2024 Jul 10:S0190-9622(24)01046.
    >> Share

  87. MCKENZIE NC, Buras MR, Yiannias JA, Hall MR, et al
    Cost-effectiveness of patch testing allergens within the same group - a computational approach to optimize formaldehyde-related allergen selection.
    J Am Acad Dermatol. 2024 Jul 5:S0190-9622(24)01000.
    >> Share

  88. BAO A, Su HJ, Wan J
    Comparative Safety Analysis of Anti-IL-4/IL-13 Inhibitors and JAK Inhibitors in Atopic Dermatitis.
    J Am Acad Dermatol. 2024 Jul 4:S0190-9622(24)01003.
    >> Share

  89. BRODELL RT
    JAAD Game Changer: Etanercept therapy for toxic epidermal necrolysis.
    J Am Acad Dermatol. 2024;91:191.
    >> Share

    June 2024
  90. GRANT-KELS JM
    JAAD Game Changers: "Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate".
    J Am Acad Dermatol. 2024 Jun 13:S0190-9622(24)00901.
    >> Share

  91. LIN TL, Fan YH, Fan KS, Juan CK, et al
    Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study.
    J Am Acad Dermatol. 2024 Jun 13:S0190-9622(24)00788.
    >> Share

  92. KEOW S, Abu-Hilal M
    Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.
    J Am Acad Dermatol. 2024 Jun 8:S0190-9622(24)00891.
    >> Share

  93. GANTZ HY, Greenzaid JD, Feldman SR
    Atopic dermatitis may not confer clinically meaningful risk of inflammatory bowel disease or renal malignancy.
    J Am Acad Dermatol. 2024 Jun 4:S0190-9622(24)00841.
    >> Share

  94. YAMANAKA-TAKAICHI M, Watanabe M, Comfere NI, Sokumbi O, et al
    Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis.
    J Am Acad Dermatol. 2024;90:1289-1291.
    >> Share

  95. CURTIS KK, Dillan MM, Sharma TR, Piktel J, et al
    COVID-19 infection increases the development of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort analysis.
    J Am Acad Dermatol. 2024;90:1300-1302.
    >> Share

  96. WANG S, Laageide L, Phan V, Rosenbach M, et al
    Use of registry surveys in cutaneous sarcoidosis.
    J Am Acad Dermatol. 2024;90:1294-1296.
    >> Share

  97. SIMPSON EL, Silverberg JI, Worm M, Honari G, et al
    Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
    J Am Acad Dermatol. 2024;90:1190-1199.
    >> Share

  98. PATTERSON A
    JAAD Game Changer: Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study.
    J Am Acad Dermatol. 2024;90:1318.
    >> Share

  99. ELSTON DM
    Letter from the Editor: Drug reaction with eosinophilia and systemic symptoms syndrome.
    J Am Acad Dermatol. 2024;90:1153-1154.
    >> Share

  100. BLUMENTHAL KG, Alvarez-Arango S, Kroshinsky D, Lo YC, et al
    Drug reaction eosinophilia and systemic symptoms: Clinical phenotypic patterns according to causative drug.
    J Am Acad Dermatol. 2024;90:1240-1242.
    >> Share

    May 2024
  101. RIGALI S, Cozzi C, Liszewski W
    Identification of the Pigments Used in Permanent Makeup and Their Ability to Elicit Allergic Contact Dermatitis.
    J Am Acad Dermatol. 2024 May 31:S0190-9622(24)00830.
    >> Share

  102. WOHLTMANN WE
    JAAD Game Changers: "Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study".
    J Am Acad Dermatol. 2024 May 30:S0190-9622(24)00824.
    >> Share

  103. UBUKATA N, Hashizume H, Nakatani E, Sasaki H, et al
    Risk Factors and Drugs Associated with the Development of Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Population-Based Cohort Study Using the Shizuoka Kokuho Database.
    J Am Acad Dermatol. 2024 May 23:S0190-9622(24)00816.
    >> Share

  104. SILVERBERG JI, Eichenfield LF, Hebert AA, Simpson EL, et al
    Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials.
    J Am Acad Dermatol. 2024 May 20:S0190-9622(24)00755.
    >> Share

  105. ELSTON DM
    This month in JAAD: May 2024.
    J Am Acad Dermatol. 2024;90:930.
    >> Share

  106. SILVERBERG JI, Kirsner RS, Margolis DJ, Tharp M, et al
    Efficacy and safety of crisaborole ointment, 2%, in participants aged >/=45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
    J Am Acad Dermatol. 2024;90:945-952.
    >> Share

  107. ZHANG L, Li X, Xu X, Le Y, et al
    Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells.
    J Am Acad Dermatol. 2024;90:970-976.
    >> Share

  108. SAKUNCHOTPANIT G, Rohan TZ, Milosavljevic S, Patil MK, et al
    Procalcitonin: A potentially useful serum test in patients with dermatologic disease.
    J Am Acad Dermatol. 2024;90:1090-1091.
    >> Share

  109. WOHLTMANN WE
    JAAD Game Changer: Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis in a cohort of patients.
    J Am Acad Dermatol. 2024;90:1114.
    >> Share

    April 2024
  110. ZHANG J, Boesjes CM, Loman L, Kamphuis E, et al
    Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry.
    J Am Acad Dermatol. 2024 Apr 21:S0190-9622(24)00641.
    >> Share

  111. LEIBOWITZ R, Fischer A, Collins LF, Feldman RJ, et al
    HIV-related exclusion criteria in atopic dermatitis and prurigo nodularis clinical trials.
    J Am Acad Dermatol. 2024 Apr 12:S0190-9622(24)00633.
    >> Share

  112. HASAN I, Parsons L, Duran S, Zinn Z, et al
    Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.
    J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00566.
    >> Share

  113. POWERS CM, Piontkowski AJ, Orloff J, Pulsinelli J, et al
    Risk of lymphoma in patients with atopic dermatitis: A case-control study in the All of Us database.
    J Am Acad Dermatol. 2024 Apr 4:S0190-9622(24)00554.
    >> Share

    March 2024
  114. MANZAR D, Suntres E, Nair N, Patel Y, et al
    Elevation of Creatine Phosphokinase in Moderate-Severe Atopic Dermatitis is Associated with the use of JAK inhibitors but not Dupilumab: A Systematic Review and Meta-Analysis.
    J Am Acad Dermatol. 2024 Mar 28:S0190-9622(24)00538.
    >> Share

  115. HREN MG, Guenin S, Khattri S
    Successful use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease.
    J Am Acad Dermatol. 2024 Mar 15:S0190-9622(24)00492.
    >> Share

    October 2023
  116. RONNSTAD ATM, Thomsen SF, Thyssen JP, Egeberg A, et al
    The burden of head-and-neck dermatitis in adults with atopic dermatitis and its association with asthma, rhinitis, and disease severity.
    J Am Acad Dermatol. 2023 Oct 28:S0190-9622(23)03046.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016